Cannabis firm valued at £175m on AIM
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Geoffrey Guy, the chief executive of GW Pharmaceuticals, will see his paper fortune valued at £47m when the company that develops prescription drugs containing cannabis floats on the junior AIM stock market next Thursday.
The company has raised £25m through placing a 14.3 per cent stake at 182p a share that was six times oversubscribed. It will float with a market capitalisation of £175m.
GW, founded by Dr Guy three years ago, increased the number of new shares it offered to institutions following strong demand. It had orginally hoped to raise £16m of fresh funds.
It will plough the cash into clinical trials of its treatments for multiple sclerosis (MS) and cancer pain. If the trials are a success, GW hopes to apply for regulatory approval from Britain's Medicines Control Agency in 2003 and begin selling the drugs in early 2004.
Dr Guy, who also co-founded the quoted plant medicines company Phytopharm in 1989, owns 27 per cent of GW and is the company's biggest single shareholder.
The company's directors together control 45.8 per cent of GW and have agreed not to sell any shares for at least 12 months after the float and no more than half their holdings for a further six months. Two other shareholders with 10.9 per cent of GW have agreed a 12 month lock-in.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments